Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01834612 | Evaluation of the Zynex Blood Volume Monitor in Healthy Adult Volunteers During a Blood Draw | PHASE1 | COMPLETED | 20 | — | — | Jan 7, 2013 | Mar 11, 2013 | Jul 21, 2021 | 1 | United States |
| NCT01646060 | Clinical Evaluation of the Zynex Blood Volume Monitor (CM-1500) in Healthy Male Adult Subjects During a Blood Draw | PHASE1 | COMPLETED | 10 | — | — | Nov 1, 2011 | Dec 1, 2011 | Jul 20, 2012 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| Blood draw | ACTIVE_COMPARATOR | CM1500 with blood draw |
| No blood draw | SHAM_COMPARATOR | CM 1500 with no blood draw |
| Name | Type | Description |
|---|---|---|
| CM1500 | DEVICE | blood volume monitor |
| CM-1500 | DEVICE | Blood Volume Monitor |
Inclusion Criteria: * healthy volunteer * between 18 to 50 years of age * weight between 157 to 220 lbs Exclusion Criteria: * unstable or untreated cardia disease * alcohol consumption in 24 hours prior to screening * tobacco use in 4 hours prior to screening * pregnancy * infection * Hemoglobin ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | VRTX | 1 | PHASE3 | CTX001 |
| Incyte Corporation | INCY | 1 | PHASE2 | Ruxolitinib |
| Molecular Partners AG Sponsored ADR | MOLN | 1 | PHASE1 | MP0533 monotherapy, Part 1 |
| Abbott Laboratories | ABT | 2 | NA | Undisclosed |
| Sangamo Therapeutics, Inc. | SGMO | 1 | — | BIVV003, ST-400 |